Relationship of Demographic, Dietary, and Clinical Factors to the Hydration Status of Patients on Peritoneal Dialysis

2004 ◽  
Vol 24 (3) ◽  
pp. 231-239 ◽  
Author(s):  
Ramzana B. Asghar ◽  
Sandra Green ◽  
Barbara Engel ◽  
Simon J. Davies
Keyword(s):  
Body Weight ◽  
Peritoneal Dialysis ◽  
Solute Transport ◽  
Extracellular Fluid ◽  
Fat Free Mass ◽  
Single Frequency ◽  
Hydration Status ◽  
Clinical Factors ◽  
Membrane Function ◽  
Fluid Removal

Objectives To establish which clinical factors are associated with an increased proportion of extracellular fluid (ECF) in peritoneal dialysis (PD) patients. Design A single-center, cross-sectional analysis of 68 stable PD patients. Method Bioelectrical impedance measurements (RJL, single frequency; RJL Systems, Clinton, Michigan, USA) of resistance and reactance were used to determine the proportion of ECF comprising total body water (TBW) in 68 stable PD patients attending for routine clearance and membrane studies. All patients underwent detailed dietetic, adequacy, and membrane function tests. Blood pressure and antihypertensive requirements were also documented. Results Significant gender differences in body composition were observed, such that women had lower absolute TBW and fat-free mass per kilogram body weight, but proportionately more ECF for a given TBW, mean ECF:TBW 0.5 ± 0.03 versus 0.44 ± 0.05, p < 0.005. In view of this, patients were split into two groups, defined as “over-” or “normally” hydrated, either by using the single discriminator (median ECF:TBW = 0.47) for the whole population, which resulted in groups distorted by gender, or by using different discriminators according to gender (women: 0.49, men 0.45). In both analyses, overhydrated patients were older, had significantly lower plasma albumin, less total fluid removal per kilogram body weight, and higher peritoneal solute transport. When split by a single discriminator, the overhydrated patients had lower sodium removal and significantly less intracellular fluid volume due to an excess of women in this group who also had less residual function and had been on dialysis longer. Using gender-specific discrimination, overhydrated patients were heavier due to expansion of the ECF volume: 20 ± 4.1 L versus 16 ± 3.3 L, p < 0.001. Stepwise multivariate analysis found age ( p = 0.001), albumin ( p = 0.009), and fluid losses per kilogram body weight ( p = 0.025) to be independent predictors of gender-adjusted hydration status. Sodium intake did not vary according to hydration status. Conclusion Gender influences the assessment of hydration status of PD patients when employing bioimpedance, such that women tend to have more ECF. Taking this into account, age, albumin, and achieved fluid removal appear to be independently associated with hydration status, whereas peritoneal solute transport is not. Advice on dietary sodium should take account of hydration status and achievable losses.

Taking Peritoneal Dialysis beyond the Year 2000

1999 ◽  
Vol 19 (3_suppl) ◽  
pp. 35-42 ◽  
Author(s):  
Ram Gokal
Keyword(s):  
Peritoneal Dialysis ◽  
Peritoneal Membrane ◽  
Membrane Function ◽  
Fluid Removal ◽  
The Past ◽  
First Choice ◽  
Year 2000 ◽  
Economic Considerations ◽  
Appropriate Prescription ◽  
Better Than

Over the past 25 years, peritoneal dialysis (PD) has steadily improved so that now its outcomes, in the form of patient survival, are equivalent to, and at times better than, those for hemodialysis. We now have a better understanding of the pathophysiology of peritoneal membrane function and damage and the importance of appropriate prescription to meet agreed-upon targets of solute and fluid removal. In the next millennium, greater emphasis will be put on prescription setting and subsequent monitoring. This will entail an increase in automated PD, especially for lifestyle reasons as well as for patients with a hyperpermeable peritoneal membrane. To improve outcomes, dialysis should be started earlier than is currently the case. It is easy to do this with PD, where an incremental approach is made easier by the introduction of icodextrin for long-dwell PD. In the future, solutions will be tailored to be more biocompatible and to provide improved nutrition and better cardiovascular outcomes. Finally, economic considerations favor PD, which is cheaper than in-centre hemodialysis. Thus, for many, PD has become a first-choice therapy, and with further improvements this trend will continue.

scholarly journals Glucose absorption from peritoneal dialysate is associated with a gain in fat mass and a reduction in lean body mass in prevalent peritoneal dialysis patients

2020 ◽  
Vol 123 (11) ◽  
pp. 1269-1276
Author(s):  
Steven Law ◽  
Andrew Davenport
Keyword(s):  
Body Composition ◽  
Peritoneal Dialysis ◽  
Weight Gain ◽  
Fat Mass ◽  
Glucose Absorption ◽  
Fat Free Mass ◽  
Osmotic Gradient ◽  
Membrane Function ◽  
Pd Membrane ◽  
Male Sex

AbstractThe majority of peritoneal dialysates use glucose to generate an osmotic gradient for the convective removal of water and Na. Although glucose can potentially be absorbed, previous studies have failed to establish whether this leads to increased fat weight gain. We measured body composition using bioimpedance in peritoneal dialysis (PD) patients, electively starting PD, attending for their first assessment of peritoneal membrane function after 2–3 months, and then after 12 months. We studied 143 patients: eighty-nine (62·2 %) males, fifty-three (37·1 %) diabetics, mean age 61·3 (SD 14·9) years, with ninety (62·1 %) patients treated by automated PD cyclers with a daytime icodextrin exchange and thirty-seven (25·9 %) by continuous ambulatory PD. Median fat mass increased by 1·8 (–0·5 to 4·1) kg, whereas fat-free mass fell –1·3 (–2·9 to 1·0) kg, and the increase in fat mass was negatively associated with the fall in soft lean mass (r –0·41, P < 0·001). Increased fat mass was associated with measured peritoneal glucose absorption (r 0·69, P < 0·001), and glucose absorption was associated with the amount of 22·7 g/l glucose dialysate (OR 2·0, 95 % CI 1·5, 2·5, P < 0·001), peritoneal urea clearance (OR 9·5, 95 % CI 2·4, 37·1, P = 0·001) and male sex (OR 4·8, 95 % CI 1·5, 14·9, P = 0·008). We report an observational study in prevalent PD patients following body composition from their first assessment of PD membrane function for approximately 12 months, and despite the majority of patients prescribed icodextrin, we have demonstrated not only an association between intra-peritoneal glucose absorption and fat weight gain but also loss of fat-free mass.

Monitoring of Long-Term Peritoneal Membrane Function

2001 ◽  
Vol 21 (2) ◽  
pp. 225-232 ◽  
Author(s):  
Simon J. Davies
Keyword(s):  
Peritoneal Dialysis ◽  
Solute Transport ◽  
Water Transport ◽  
Drop Out ◽  
Published Data ◽  
Peritoneal Membrane ◽  
Membrane Function ◽  
Technique Survival ◽  
Ultrafiltration Failure

Objective Peritoneal membrane function influences dialysis prescription and clinical outcome and may change with time on treatment. Increasingly sophisticated tools, ranging from the peritoneal equilibration test (PET) to the standard permeability analysis (SPA) and personal dialysis capacity (PDC) test, are available to the clinician and clinical researcher. These tests allow assessment of a number of aspects of membrane function, including solute transport rates, ultrafiltration capacity, effective reabsorption, transcellular water transport, and permeability to macromolecules. In considering which tests are of greatest value in monitoring long-term membrane function, two criteria were set: those that result in clinically relevant interpatient differences in achieved ultrafiltration or solute clearances, and those that change with time in treatment. Study Selection Clinical validation studies of the PET, SPA, and PDC tests. Studies reporting membrane function using these methods in either long-term (5 years) peritoneal dialysis patients or longitudinal observations (> 2 years). Data Extraction Directly from published data. Additional, previously unpublished analysis of data from the Stoke PD Study. Results Solute transport is the most important parameter. In addition to predicting patient and technique survival at baseline, there is strong evidence that it can increase with time on treatment. Whereas patients with initially high solute transport drop out early from treatment, those with low transport remain longer on treatment, although, over 5 years, a proportion develop increasing transport rates. Ultrafiltration capacity, while being a composite measure of membrane function, is a useful guide for the clinician. Using the PET (2.27% glucose), a net ultrafiltration capacity of < 200 mL is associated with a 50% chance of achieving less than 1 L daily ultrafiltration at the expense of 1.8 hypertonic (3.86%) exchanges in anuric patients. Using a SPA (3.86% glucose), a net ultrafiltration capacity of < 400 mL indicates ultrafiltration failure. While there is circumstantial evidence that, with time on peritoneal dialysis, loss of transcellular water transport might contribute to ultrafiltration failure, none of the current tests is able to demonstrate this unequivocally. Of the other membrane parameters, evidence that interpatient differences are clinically relevant (permeability to macro-molecules), or that they change significantly with time on treatment (effective reabsorption), is lacking. Conclusion A strong case can be made for the regular assessment by clinicians of solute transport and ultrafiltration capacity, a task made simple to achieve using any of the three tools available.

Effects of Chondroitin Sulphate on Fluid and Solute Transport during Peritoneal Dialysis in Rats

1991 ◽  
Vol 11 (4) ◽  
pp. 351-354 ◽  
Author(s):  
Andrzej Breborowicz ◽  
Maciej Radkowski ◽  
Jan Knapowski ◽  
Dimitrios G. Oreopoulos
Keyword(s):  
Peritoneal Dialysis ◽  
Hydrostatic Pressure ◽  
Hydraulic Conductivity ◽  
Horseradish Peroxidase ◽  
Solute Transport ◽  
Peritoneal Cavity ◽  
Chondroitin Sulphate ◽  
In Vitro Experiments ◽  
Fluid Removal

The effect of chondroitin sulphate (CS) on peritoneal fluid and solute transport was studied in rats undergoing peritoneal dialysis. In the presence of CS, net ultrafiltration increased, while absorption of glucose and horseradish peroxidase from the peritoneal cavity decreased. Albumin, used instead of CS, did not modify either fluid or solute transport. In in vitro experiments on isolated rabbit mesentery, CS decreased transmembrane water flow induced by hydrostatic pressure, and its effect was not fully reversed 60 minutes after “wash-out” of this glycosaminoglycan. We postulate that the polyanionic CS molecules are trapped in the peritoneal interstitium, thus decreasing its hydraulic conductivity and permeability, which in turn increases net fluid removal during peritoneal dialy sis because of its slower absorption from the peritoneal cavity.

Peritoneal Solute Clearances in Diabetics

1990 ◽  
Vol 10 (1) ◽  
pp. 85-88 ◽  
Author(s):  
Hi Bahl Lee ◽  
Min Sun Park ◽  
Sung Hee Chung ◽  
Young Bae Lee ◽  
Kyung Soo Kim ◽  
...  
Keyword(s):  
Body Weight ◽  
Peritoneal Dialysis ◽  
Solute Transport ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Vascular Diseases ◽  
Glucose Absorption ◽  
Peritoneal Membrane ◽  
Before And After ◽  
Esrd Patients

In order to examine solute transport across the peritoneal membrane and responsiveness of the peritoneal microcirculation to a vasodilator in diabetics on continuous ambulatory peritoneal dialysis (CAPD), we obtained peritoneal clearances of urea (Curea) and creatinine (Ccr), protein concentrations in the drained dialysate (D PC), and percentage of peritoneal glucose absorption (% PGA) before and after nitroprusside (NP) addition to the dialysate in 13 diabetics (DM) and 13 nondiabetics (non-DM) matched for age, sex, body weight, and duration of CAPD. Control (before NP) Curea, Ccr, D PC, and %PGA were not different between DM and non-DM. NP significantly enhanced Curea, Ccr, and D PC in both DM and non-DM. Curea, Ccr, D PC, and %PGA after NP were again not different between DM and non-DM. The findings suggest that peritoneal solute clearances and responsiveness of the peritoneal microcirculation to NP in diabetics are not different from nondiabetics at the beginning of CAPD despite evidence for widespread vascular diseases in diabetic ESRD patients.

Peritoneal dialysis

2020 ◽  
pp. 4874-4879
Author(s):  
Simon Davies
Keyword(s):  
Peritoneal Dialysis ◽  
Kidney Injury ◽  
Peritoneal Membrane ◽  
Dialysis Fluid ◽  
Membrane Function ◽  
Fluid Removal ◽  
Visceral Peritoneum ◽  
Life Threatening ◽  
Gram Negative Organisms ◽  
Capillary Circulation

Peritoneal dialysis is achieved by repeated cycles of instillation and drainage of dialysis fluid within the peritoneal cavity, with the two main functions of dialysis—solute and fluid removal—occurring due to the contact between dialysis fluid and the capillary circulation of the parietal and visceral peritoneum across the peritoneal membrane. It can be used to provide renal replacement therapy in acute kidney injury or chronic kidney disease. Practical aspects—choice of peritoneal dialysis as an effective modality for renal replacement in the short to medium term (i.e. several years) is, for most patients, a lifestyle issue. Typically, a patient on continuous ambulatory peritoneal dialysis will require three to four exchanges of 1.5 to 2.5 litres of dialysate per day. Automated peritoneal dialysis and use of the glucose polymer dialysis solution icodextrin enables flexibility of prescription that can mitigate the effects of membrane function (high solute transport). Peritonitis—this remains the most common complication of peritoneal dialysis, presenting with cloudy dialysis effluent, with or without abdominal pain and/or fever, and confirmed by a leucocyte count greater than 100 cells/µl in the peritoneal fluid. Empirical antibiotic treatment, either intraperitoneal or systemic, with cover for both Gram-positive and Gram-negative organisms, should be commenced immediately while awaiting specific cultures and sensitivities. Long-term changes in peritoneal membrane function influence survival on peritoneal dialysis if fluid removal is less efficient (ultrafiltration failure), especially in the absence of residual kidney function. This is the main limitation of treatment, along with avoiding the risk of encapsulating peritoneal sclerosis—a life-threatening complication of peritoneal dialysis, particularly if of long duration (15–20% incidence after 10 years), that is characterized by severe inflammatory thickening, especially of the mesenteric peritoneum, resulting in an encapsulation and progressive obstruction of the bowel.

Peritoneal Dialysis in Anuric Patients: Old Problems and New Perspectives

2009 ◽  
Vol 29 (2_suppl) ◽  
pp. 233-235
Author(s):  
Anabela S. Rodrigues
Keyword(s):  
Peritoneal Dialysis ◽  
Clinical Evidence ◽  
Risk Group ◽  
Membrane Function ◽  
Fluid Removal

Anuric patients are often excluded from peritoneal dialysis (PD) because of the fear that PD is inadequate to treat this higher-risk group of patients. However, advances in PD knowledge and technique allow better and adjusted treatments. There is now clinical evidence that anuric patients can be successfully treated with PD, while new solutions promise to mitigate some limitations of automated PD, such as sodium and fluid removal and preservation of membrane function.

Peritoneal Dialysis in the Patient with a Failing Renal Allograft

2001 ◽  
Vol 21 (3_suppl) ◽  
pp. 280-284 ◽  
Author(s):  
Simon J. Davies
Keyword(s):  
Peritoneal Dialysis ◽  
Cardiovascular Risk ◽  
Solute Transport ◽  
Cox Regression ◽  
Post Transplantation ◽  
Plasma Albumin ◽  
Membrane Function ◽  
Transplant Patients ◽  
Co Morbidity ◽  
Significant Difference

Background Patients returning to dialysis treatment after a period with a functioning allograft represent a special case in the integrated care model of renal replacement therapy. They are known to nephrologists— and thus are ideal candidates for a timely commencement of dialysis—but they have had time to accrue additional cardiovascular risk. Furthermore, they have been exposed to prolonged immunosuppression. Purpose The present study aimed to establish the clinical outcomes of patients returning to peritoneal dialysis (PD) with failing allografts [survival, technique survival, longitudinal residual renal function (Kt/VR), peritoneal membrane function (solute transport), and plasma albumin] and to compare those outcomes with outcomes in new, contemporary patients. Setting The study was conducted in a single center where prospective collection of data now known to be important in determining outcome on peritoneal dialysis (age, comorbidity, albumin, Kt/VR, and solute transport) has been performed since 1989. Methods All patients commencing PD between 1989 and 2001 after failure of an allograft that had functioned for more than 6 months were identified. Outcomes in that group were compared to outcomes in all new PD patients and in all dialysis patients with failed grafts who were returning to hemodialysis (HD) in the same period. Results The study identified 45 patients with failed allografts: 28 were commencing PD treatment, and 17 were commencing HD treatment. Those patients were significantly younger than the 469 new patients commencing PD [FailedTx→ PD 41.2 years, FailedTx→ HD 38.9 years, NewPD 54.7 years; analysis of variance (ANOVA): p < 0.001]. We saw no significant difference in the survival of failed transplant patients commencing PD as compared with those commencing HD (log rank: p = 0.11). Kaplan–Meier plots of patient survival were better for failed transplant patients as compared with all new PD patients. When corrected using Cox regression, the survival advantage was seen to be due to age and comorbidity at start of PD. Pure technique failure (excluding death) was not different between the groups. Compared with all new PD patients, patients with failed allografts had similar longitudinal plasma albumin and a tendency toward an earlier increase in solute transport, but a more rapid loss of Kt/VR, ( p < 0.05 at 6 – 48 months). Conclusions Peritoneal dialysis would appear to be a good option for patients with failing allografts. Co-morbidity is the predominant determinant of survival. That finding underlines the need for attention to factors that might prevent accrual of cardiovascular risk during the post-transplantation period. The earlier loss of Kt/VR in those patients might be prevented by developing strategies of continued immunosuppression after commencement of dialysis, although infection risk is an important issue.

Inflammation and Extracellular Volume Expansion are Related to Sodium and Water Removal in Patients on Peritoneal Dialysis

2006 ◽  
Vol 26 (5) ◽  
pp. 574-580 ◽  
Author(s):  
Marcela Ávila-Díaz ◽  
María-de-Jesús Ventura ◽  
Delfilia Valle ◽  
Marlén Vicenté-Martínez ◽  
Zuzel García-González ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Extracellular Volume ◽  
Extracellular Fluid ◽  
Cross Sectional Study ◽  
Serum Glucose ◽  
Cross Sectional ◽  
Fluid Removal ◽  
Sodium Removal ◽  
Extracellular Volume Expansion ◽  
Total Body

Background Inflammation is an important risk for mortality in dialysis patients. Extracellular fluid volume (ECFv) expansion, a condition commonly seen in peritoneal dialysis (PD) patients, may be associated with inflammation. However, published support for this relationship is scarce. Objectives To quantify the proportion of patients on PD with inflammation and to analyze the role of ECFv expansion and the factors related to these conditions. Design A prospective, multicenter cross-sectional study in six hospitals with a PD program. Patients and Methods Adult patients on PD were studied. Clinical data, body composition, and sodium and fluid intake were recorded. Biochemical analysis, C-reactive protein (CRP), and peritoneal and urinary fluid and sodium removal were also measured. Results CRP values positive (≥ 3.0 mg/L) for inflammation were found in 147 (80.3%) and negative in 36 patients. Patients with positive CRP had higher ECFv/total body water (TBW) ratio (women 47.69 ± 0.69 vs 47.36 ± 0.65, men 43.15 ± 1.14 vs 42.84 ± 0.65; p < 0.05), higher serum glucose (125.09 ± 81.90 vs 103.28 ± 43.30 mg/dL, p < 0.03), and lower serum albumin (2.86 ± 0.54 vs 3.17 ± 0.38 g/dL, p < 0.001) levels. They also had lower ultrafiltration (1003 ± 645 vs 1323 ± 413 mL/day, p < 0.005) and total fluid removal (1260 ± 648 vs 1648 ± 496 mL/day, p < 0.001), and less peritoneal (15.59 ± 162.14 vs 78.11 ± 110.70 mEq/day, p < 0.01) and total sodium removal (42.06 ± 142.49 vs 118.60 ± 69.73 mEq/day, p < 0.001). In the multivariate analysis, only ECFv/TBW was significantly ( p < 0.04) and independently associated with inflammation. ECFv/TBW was correlated with fluid removal ( r = 0.16, p < 0.03) and renal sodium removal ( r = 0.2, p < 0.01). Conclusion The data suggest that ECFv expansion may have a significant role as an inflammatory stimulus. The results disclose a relationship between the two variables, ECFv expansion and inflammation, identified as independent risk factors for mortality in PD patients.

scholarly journals Threefold Peritoneal Test of Osmotic Conductance, Ultrafiltration Efficiency, and Fluid Absorption

2013 ◽  
Vol 33 (4) ◽  
pp. 419-425 ◽  
Author(s):  
Jacek Waniewski ◽  
Ramón Paniagua ◽  
Joanna Stachowska–Pietka ◽  
María-de-Jesús Ventura ◽  
Marcela Ávila–Díaz ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Solute Transport ◽  
Peritoneal Fluid ◽  
Absorption Rate ◽  
Transport Parameter ◽  
Fluid Absorption ◽  
Transport Parameters ◽  
Fluid Removal ◽  
Modifiable Factors ◽  
Small Solute

BackgroundFluid removal during peritoneal dialysis depends on modifiable factors such as tonicity of dialysis fluids and intrinsic characteristics of the peritoneal transport barrier and the osmotic agent—for example, osmotic conductance, ultrafiltration efficiency, and peritoneal fluid absorption. The latter parameters cannot be derived from tests of the small-solute transport rate. We here propose a simple test that may provide information about those parameters.MethodsVolumes and glucose concentrations of drained dialysate obtained with 3 different combinations of glucose-based dialysis fluid (3 exchanges of 1.36% glucose during the day and 1 overnight exchange of either 1.36%, 2.27%, or 3.86% glucose) were measured in 83 continuous ambulatory peritoneal dialysis (CAPD) patients. Linear regression analyses of daily net ultrafiltration in relation to the average dialysate-to-plasma concentration gradient of glucose allowed for an estimation of the osmotic conductance of glucose and the peritoneal fluid absorption rate, and net ultrafiltration in relation to glucose absorption allowed for an estimation of the ultrafiltration effectiveness of glucose.ResultsThe osmotic conductance of glucose was 0.067 ± 0.042 (milliliters per minute divided by millimoles per milliliter), the ultrafiltration effectiveness of glucose was 16.77 ± 7.97 mL/g of absorbed glucose, and the peritoneal fluid absorption rate was 0.94 ± 0.97 mL/min (if estimated concomitantly with osmotic conductance) or 0.93 ± 0.75 mL/min (if estimated concomitantly with ultrafiltration effectiveness). These fluid transport parameters were independent of small-solute transport characteristics, but proportional to total body water estimated by bioimpedance.ConclusionsBy varying the glucose concentration in 1 of 4 daily exchanges, osmotic conductance, ultrafiltration efficiency, and peritoneal fluid absorption could be estimated in CAPD patients, yielding transport parameter values that were similar to those obtained by other, more sophisticated, methods.

Sign in / Sign up

Export Citation Format

Share Document